Related Experiment Video
Updated: Nov 27, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
Precious Barnes1, F A Yeboah2, Jinling Zhu3
1Department of Physician Assistant Studies, College of Health and Allied Sciences School of Allied Health Sciences, University of Cape Coast, Ghana.
Introduction:
Head and neck tumors (HNT) are tumors that normally occur at the head and neck region of the body. Epidermal growth factor receptor (EGFR) has been found to be highly expressed in breast and other tumors; therefore, there is the need to investigate the level of EGFR expression among patients with head and neck tumors in Ghana.
Method:
The level of EGFR expression was determined in head and neck tumor and control head and neck tissues with quantitative real-time PCR and immunohistochemistry analysis.
Results:
The level of EGFR expressions was high in tumor tissues than in the control tissues. There was a significant difference of p value 0.025 among the ages >40 and ≤ 40 when the high and low level of EGFR was compared in the head and neck malignant tumor. The area under the curve for the high expression of EGFR among the malignant head and neck tumors was 0.901 with a specificity of 86.4%.
Conclusion:
EGFR can serve as a prognostic marker in monitoring patients with HNT as well as a molecular therapeutic target.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:19Clinical Applications of Epidermal Stem Cells